400 related articles for article (PubMed ID: 35203022)
1. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy.
Zhang W; Zhao Z; Li F
Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
[TBL] [Abstract][Full Text] [Related]
5. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
6. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell-based strategies for immunotherapy of cancer.
Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
[TBL] [Abstract][Full Text] [Related]
8. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
9. NK Cell Metabolism and Tumor Microenvironment.
Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
Front Immunol; 2019; 10():2278. PubMed ID: 31616440
[TBL] [Abstract][Full Text] [Related]
10. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer.
Elanany MM; Mostafa D; Hamdy NM
Life Sci; 2023 Oct; 330():121997. PubMed ID: 37536617
[TBL] [Abstract][Full Text] [Related]
11. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
Jiang D; Zhang J; Mao Z; Shi J; Ma P
Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
[TBL] [Abstract][Full Text] [Related]
12. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions.
Russick J; Joubert PE; Gillard-Bocquet M; Torset C; Meylan M; Petitprez F; Dragon-Durey MA; Marmier S; Varthaman A; Josseaume N; Germain C; Goc J; Dieu-Nosjean MC; Validire P; Fournel L; Zitvogel L; Bindea G; Lupo A; Damotte D; Alifano M; Cremer I
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067317
[TBL] [Abstract][Full Text] [Related]
14. NK cell exhaustion in the tumor microenvironment.
Jia H; Yang H; Xiong H; Luo KQ
Front Immunol; 2023; 14():1303605. PubMed ID: 38022646
[TBL] [Abstract][Full Text] [Related]
15. The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity.
Tumino N; Nava Lauson CB; Tiberti S; Besi F; Martini S; Fiore PF; Scodamaglia F; Mingari MC; Moretta L; Manzo T; Vacca P
Int J Cancer; 2023 Apr; 152(8):1698-1706. PubMed ID: 36468179
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
Zeng Y; Lv X; Du J
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
[TBL] [Abstract][Full Text] [Related]
19. Combining radiotherapy and NK cell-based therapies: The time has come.
Baude J; Limagne E; Ladjohounlou R; Mirjolet C
Int Rev Cell Mol Biol; 2023; 378():31-60. PubMed ID: 37438020
[TBL] [Abstract][Full Text] [Related]
20. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
